Cancer Discov:雌激素驱动免疫抑制,促进肿瘤恶化

2016-10-29 生物探索 生物探索

CRISPR–Cas9工具使得科学家们能够几乎随意地改变基因组。人们称赞它比以往的技术明显更简单、更廉价及更通用,CRISPR–Cas9在全球各地的实验室中大放光彩,已发现了一些医学和基础研究的新应用。但CRISPR–Cas9有其局限性。CRISPR–Cas9工具使得科学家们能够几乎随意地改变基因组。人们称赞它比以往的技术明显更简单、更廉价及更通用,CRISPR–Cas9在全球各地的实验室中大放光

近期,《Cancer Discovery》期刊发表一篇最新文章揭示,雌激素会在肿瘤微环境中发挥免疫抑制功能,雌激素信号会促进癌变细胞的增殖和恶化。这一最新研究成果有助于推动“免疫治疗+抗雌激素药物”的抗癌新策略,有望显著延长癌症患者的生存时间。




对于乳腺癌、卵巢癌而言,雌激素影响肿瘤发展很好理解,但是它抑制抗肿瘤免疫的机制尚未被研究清晰。

近期,美国Wistar研究所最新发现,雌激素信号在肿瘤微环境中行使免疫抑制功能。这一研究成果有助于推进免疫治疗与抗雌激素药物结合,从而显著延长癌症患者的生存时间。相关研究成果发表在《Cancer Discovery》期刊。

雌激素信号促进肿瘤组织增长、恶化

雌性激素会与两个高度亲和性受体——ERα、ERβ结合。当肿瘤组织呈现ER阳性,雌激素会传递信号,促进肿瘤增长和恶化。正因为如此,ER阳性乳腺癌常常需要接受抗雌激素治疗,例如他莫昔芬(tamoxifen)。这种治疗策略会降低肿瘤组织中的雌激素信号,但是它会增加身体其他部位的雌激素信号。

Wistar研究所的肿瘤微环境及转移研究教授José R. Conejo-Garcia博士解释:“我们已经知道,雌激素对肿瘤细胞的直接影响,而肿瘤微环境也肿瘤的恶性发展、抗癌药物的效果起着关键作用。同时,大多数免疫细胞都表达有雌激素受体,所以我们推测,雌激素在癌症发展过程中势必发挥着重大作用。”

为了验证猜想,Conejo-Garcia团队进行了一系列动物和体外试验。结果发现,雌激素信号会促进髓源性抑制细胞(MDSCs)的聚集,并增强细胞活跃度。MDSCs属于免疫细胞,与肿瘤治疗抗性有关。这意味着,雌激素会联合髓源性抑制细胞“双管齐下”,抑制抗癌免疫。

以动物为模型发现,补充雌激素会促进肿瘤的生长,而切除卵巢阻断刺激分泌后,动物体内抗肿瘤免疫活性增强,肿瘤恶化被延迟。重要的是,对于免疫缺陷小鼠,肿瘤恶化并没有差异。这意味着,雌激素促进肿瘤生长的作用依赖于抗肿瘤免疫的抑制程度。

此外,Conejo-Garcia团队发现ERα雌激素受体责激活STAT3 信号通路(与癌细胞生存、MDSCs聚集有关联)。同时,ERα可以通过激活JAK2、SRC蛋白的活力,激活 STAT3通路。

这些信号通路会在乳腺癌、卵巢癌、黑色素瘤等癌症中被激活。考虑到雌激素广泛存在,包括男人和绝经后的女性,所以研究人员认为,研究抗雌激素治疗策略能够对多种癌症提供新的治疗策略,且这一策略可以阻断髓源性抑制细胞和肿瘤的增殖、恶化。

原始出处:

[1] Estrogen signaling impacted immune response in cancer. Scinece Daily. October 17, 2016.

[2] Nikolaos Svoronos,et al. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Supressor Cells. CANCER DISCOVERY. 30 September 2016.DOI: 10.1158/2159-8290.CD-16-0502 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-11-02 1e10c84am36(暂无匿称)

    好可怕

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-11-01 Davidyang1219

    厉害了,我的哥,很有创意,很新颖

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-31 yankaienglish
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-30 忠诚向上

    好好看看

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-30 刘煜

    对抗肿瘤又一希望。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-29 上邪zyy

    看看

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2012145, encodeId=a3ff2012145a4, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Tue May 23 15:00:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152842, encodeId=3ea115284286, content=好可怕, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Nov 02 08:54:54 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152693, encodeId=766f152693e4, content=厉害了,我的哥,很有创意,很新颖, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=19961945238, createdName=Davidyang1219, createdTime=Tue Nov 01 16:14:29 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587803, encodeId=4c08158e80396, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Mon Oct 31 07:00:00 CST 2016, time=2016-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152091, encodeId=12171520912e, content=好好看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Oct 30 07:22:11 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152084, encodeId=bc7f15208448, content=对抗肿瘤又一希望。, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Oct 30 05:36:28 CST 2016, time=2016-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152032, encodeId=c4d6152032ea, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f261920920, createdName=上邪zyy, createdTime=Sat Oct 29 18:47:06 CST 2016, time=2016-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152025, encodeId=0eb7152025fd, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151110/IMG5641A6F12C0732294.jpg, createdBy=2f901662448, createdName=乐奕11, createdTime=Sat Oct 29 16:45:46 CST 2016, time=2016-10-29, status=1, ipAttribution=)]
    2016-10-29 乐奕11

    厉害

    0

相关资讯

Biology of Sex Differences:如何根据月经期激素水平变化成功戒烟?

众所周知,尼古丁易使人上瘾,同时对人体健康有不利影响。CDC指出,每年美国有48万人的死亡是由于吸烟引起,占所有死亡人数的1/5。在美国,民众对尼古丁的成瘾度超过其他药物。虽然大家都知道吸烟的危害,但是戒烟并不是一件容易的事情。因此,研究人员指出,让民众戒掉吸烟的坏习惯十分重要。既往研究表明,女性比男性更难戒烟成功,由于吸烟,女性患冠心病和慢性阻塞性肺疾病(COPD)的风险比男性高25%。最近的一

JCEM:使用含雌激素避孕药可增加25(OH)D的浓度

既往小型研究已经表明外源性雌激素可能改善维生素D的水平,但是其机制并不清楚,因为使用激素的女性其选择的生活方式可能会影响维生素D的状态。本研究旨在探究激素避孕与25羟基维生素D(25(OH)D)之间的关联。 采用横截面数据的线性回归模型来评估校正其他混杂因素后,季节调整后的血清25(OH)D与雌激素使用之间的关联。 研究共纳入了1662名参与子宫肌瘤队列研究的非裔美国妇女,年龄在23

Menopause :Ospemifene可使更年期女性出现潮热表现

一项随机试验指出,女性在服用ospemifene前4周会出现潮热表现。 维尔弗吉尼亚大学的JoAnn Pinkerton博士指出,服用该药物的女性应该被告知服用药物后4周内会出现潮热表现,且女性也不应潮热反应的增加而停止服用该药物。 Ospemifene是日本野义制药公司开发的新一代选择性雌激素受体调节剂(SERM),于2013年2月26日获美国FDA批准上市,商品名为Osphena。该药为口服片

更年期激素治疗是利是弊?

更年期是否需要激素治疗仍然是争议话题,为此国际绝经协会出台了最新的指南,为临床医生提供指导。

J Clin Endocrinol Metab:含雌激素的避孕药可增加血清25(OH)D浓度

背景和目的:小的研究表明外源性雌激素可能改善维生素D的状态,但因果关系目前还不清楚,因为使用激素的妇女可能会改变生活方式的选择,差异影响维生素D的状态。研究者进行了一项研究,调查使用激素避孕和25羟基维生素D(25(OH)D)之间的关联。方法:使用横截面数据的线性回归模型估计季节调整后的血清25(OH)D和雌激素使用之间的关系;研究共纳入了1662名非裔美国女性,年龄23-34岁,获取了血液样本、

盘点:关于雌激素你需要了解这些

雌激素是一种女性激素,主要由卵巢和胎盘产生。进入青春期后,卵巢开始分泌雌激素,促进阴道、子宫、输卵管和卵巢的发育。雌激素还能促使皮下脂肪富集,体态丰满;乳腺增生,乳头及乳晕颜色变深,并产生性欲;促使体内钠和水的潴留,骨中钙的沉积等。这里小M整理了2016年以来关于雌激素的重要研究进展与大家分享。【1】含雌激素的避孕药可增加血清25(OH)D浓度小的研究表明外源性雌激素可能改善维生素D的状态,但